Adding cetuximab to chemotherapy led to worse outcomes for patients with resectable liver metastases caused by colorectal cancer, updated data from the New EPOC trial showed.
Updated data from KEYNOTE-010 showed superior outcomes for pembrolizumab compared with docetaxel in patients with PD-L1‒expressing advanced NSCLC.
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
Larotrectinib appeared to have durable efficacy and long-term safety in patients with TRK fusion-positive cancer.
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
A study found that young women in the United States had a higher incidence of lung cancer that could not be explained by known risk factors, such as smoking.
The addition of atezolizumab to standard chemotherapy does not appear to increase the treatment burden in patients with extensive-stage small-cell lung cancer.
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.
For older patients with follicular lymphoma, receipt of appropriate therapy for this disease was associated with a significant gain in overall survival.
